CN Patent

CN120383595A — 抑制cdk4/6活性化合物的半l-酒石酸盐一水合物

Assigned to Betta Pharmaceuticals Co Ltd · Expires 2025-07-29 · 1y expired

What this patent protects

本发明涉及抑制CDK4/6活性化合物的半L‑酒石酸盐一水合物(式II)以及其制备方法、药用组合物，和其在抑制CDK4/6的活性中的应用。

USPTO Abstract

本发明涉及抑制CDK4/6活性化合物的半L‑酒石酸盐一水合物(式II)以及其制备方法、药用组合物，和其在抑制CDK4/6的活性中的应用。

Drugs covered by this patent

Patent Metadata

Patent number: CN120383595A
Jurisdiction: CN
Classification: —
Expires: 2025-07-29
Drug substance claim: No
Drug product claim: No
Assignee: Betta Pharmaceuticals Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.